EC Approves Extended Invokana Indication On Renal Outcomes In DKD
First SGLT2 Inhibitor In Europe To Gain Extended Indication
Mundipharma has announced the European Commission’s extension of the indications for Invokana to include renal outcomes data from the Phase III CREDENCE study.
